Augmedics, Inc.

Augmedics Ltd. , based in the US, specializes in enhancing spine surgery through its innovative xvision Spine System, which integrates augmented reality technology for improved surgical navigation and patient outcomes. Founded in 2014, Augmedics, Inc. operates out of Arlington Heights, US, focusing on advanced surgical navigation solutions.

The company was co-founded by Nessi Benishti and Nissan Elimelech. Augmedics successfully raised USD 82. 5 mn in Series D funding on June 27, 2023, with lead investment from CPMG, and other participants including H. I.

G. Capital and Revival Healthcare Capital. This round brought the total amount raised to USD 82. 5 mn and the company’s current valuation to USD 238.

67 mn. Augmedics focuses on revolutionizing spine surgery through its flagship product, the xvision Spine System, which employs augmented reality (AR) technology to enhance surgical navigation. This system allows surgeons to visualize 3D anatomical structures superimposed onto the patient while maintaining direct eye contact with the surgical field, thus enhancing accuracy, efficiency, and patient safety during a range of spinal operations. The xvision Spine System is FDA approved for various procedures and is marketed to hospitals and surgical centers worldwide, particularly in North America and Europe.

Augmedics generates revenue primarily through the sale and integration of its xvision Spine System into healthcare facilities, including installation and training services. This B2B model is structured to facilitate the adoption of advanced surgical technology by healthcare providers, enhancing the quality of patient care. Revenue streams include direct sales and ongoing support services, reflecting the company's focus on comprehensive solutions for effective surgical practice integration. Following its Series D funding round in June 2023, where Augmedics raised USD 82.

5 mn, the company plans to utilize these resources to enhance its technology and support its expansion within the US market. Future growth strategies include developing new surgical products and entering additional geographic markets, although specific details on new product launches have yet to be disclosed.